BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 4.7% Higher – Time to Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares traded up 4.7% during trading on Monday . The company traded as high as $7.75 and last traded at $7.75. 1,648,389 shares were traded during mid-day trading, a decline of 41% from the average session volume of 2,793,625 shares. The stock had previously closed at $7.40.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on BCRX shares. Evercore ISI lifted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 10th. Wedbush started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Stock Up 1.8 %

The firm has a 50 day simple moving average of $7.82 and a 200-day simple moving average of $7.74. The stock has a market cap of $1.57 billion, a P/E ratio of -12.34 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period last year, the business posted $0.28 earnings per share. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new stake in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $33,000. GAMMA Investing LLC grew its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth about $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $48,000. Finally, KBC Group NV raised its position in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 4,537 shares in the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.